| abstract |
The invention relates to a pharmaceutically active H2 relaxin for use in the treatment of dyspnea in a human subject, wherein the dyspnea is associated with acute heart failure. Methods of treating acute decompensated heart failure in patients displaying particular symptoms or heart failure signs, such as high blood pressure and low cardiac output are also disclosed as are dosage regimes for the administration of the H2 relaxin. |